Sanofi Highlights Data from P-II Trial of Rilzabrutinib to Treat Moderate-to-Severe Asthma at ATS 2024
Shots:
- The P-II PoC trial evaluates rilzabrutinib's (800mg & 1200mg, QD) safety, efficacy & tolerability vs PBO added to ICS/LABA background therapy for treating moderate-to-severe asthma patients not controlled on ICS plus LABA therapy
- The study depicted a 36% (high dose) & 25% (low dose) reduced risk in LOAC events at wk.12 plus improved asthma symptoms with a mean difference of -0.54/-0.59 LS in asthma control questionnaire, ACQ-5 at wk.2. This data will form the basis of P-III study to assess drug’s BID dosing
- Furthermore, the drug was well-tolerated without any occurrences of cytopenia, hemorrhagic events, atrial fibrillation & imbalance in liver function tests with 10.9% (high dose) & 9.4% (low dose) vs 0% & 3.1% TEAEs
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
